Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 9/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.50 |
| ▸ | EGFR | P00533 | 5/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | TTK | P33981 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21876504 | 1.00 | WEE1 (0.55) | WEE1CYP3A4KCNH2TNK2EGFR | |
| SCHEMBL21876474 | 0.93 | WEE1 (0.56) | WEE1CYP3A4KCNH2TNK2EGFR | |
| SCHEMBL29776283 | 0.93 | WEE1 (0.56) | WEE1CYP3A4KCNH2TNK2EGFR | |
| SCHEMBL21876481 | 0.86 | WEE1 (0.57) | WEE1CYP3A4KCNH2TNK2EGFR | |
| SCHEMBL21876523 | 0.85 | WEE1 (0.58) | WEE1CYP3A4KCNH2TNK2SRC | |
| SCHEMBL29776165 | 0.85 | WEE1 (0.58) | WEE1CYP3A4KCNH2TNK2SRC | |
| SCHEMBL21876459 | 0.85 | TNK2 (0.52) | WEE1CYP3A4KCNH2TNK2EGFR | |
| SCHEMBL21876527 | 0.84 | WEE1 (0.55) | WEE1CYP3A4KCNH2TNK2EGFR | |
| SCHEMBL21876482 | 0.82 | EGFR (0.54) | WEE1CYP3A4KCNH2TNK2EGFR | |
| SCHEMBL21876470 | 0.81 | WEE1 (0.55) | WEE1CYP3A4KCNH2TNK2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118338905-A | Use of Wee1 kinase inhibitors in the treatment of cancer | 上海瑛派药业有限公司 | 2024-07-12 | — | — | CN | claimed |
| CN-117202908-A | Use of Wee1 kinase inhibitors in the treatment of cancer diseases | 上海瑛派药业有限公司 | 2023-12-08 | — | — | CN | claimed |
| WO-2023093840-A1 | USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER | IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) | 2023-06-01 | — | — | WO | claimed |
| WO-2022188802-A1 | USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER | IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) | 2022-09-15 | — | — | WO | claimed |
| CN-110914277-B | Imidazo [1,2-b ] pyrimido [4,5-d ] pyridazin-5 (6H) -one compounds and application thereof | 上海瑛派药业有限公司 | 2022-08-09 | — | — | CN | claimed |
| CN-118338905-A | Use of Wee1 kinase inhibitors in the treatment of cancer | 上海瑛派药业有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-117202908-A | Use of Wee1 kinase inhibitors in the treatment of cancer diseases | 上海瑛派药业有限公司 | 2023-12-08 | — | — | CN | disclosed |
| WO-2023093840-A1 | USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER | IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) | 2023-06-01 | — | — | WO | disclosed |
| WO-2022188802-A1 | USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER | IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) | 2022-09-15 | — | — | WO | disclosed |
| CN-110914277-B | Imidazo [1,2-b ] pyrimido [4,5-d ] pyridazin-5 (6H) -one compounds and application thereof | 上海瑛派药业有限公司 | 2022-08-09 | — | — | CN | disclosed |